Mark Guttman

Mark Guttman publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Mark Guttman sits on this spectrum.

Mark Guttman D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Mark Guttman sits on this spectrum.

Best Publications

• Detection of Huntington’s disease decades before diagnosis: The Predict HD study

  Jane Paulsen;Douglas R Langbehn;Julie C Stout;Elizabeth H Aylward

  969
  Citations

• Levodopa in the treatment of Parkinson's disease: current controversies.

  C. Warren Olanow;Yves Agid;Yoshi Mizuno;Alberto Albanese

  501
  Citations

• Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease

  Stephen J. Kish;Junchao Tong;Oleh Hornykiewicz;Ali Rajput

  449
  Citations

• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  Peter A. LeWitt;Peter A. LeWitt;M. Guttman;James W. Tetrud;Paul J. Tuite

  406
  Citations

• The role of radiotracer imaging in Parkinson disease

  B. Ravina;D. Eidelberg;J. E. Ahlskog;R. L. Albin

  385
  Citations

• Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease

  Mark Guttman

  287
  Citations

• Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

  Mark Stacy;Annette Bowron;Mark Guttman;Robert Hauser

  282
  Citations

• Clinical markers of early disease in persons near onset of Huntington’s disease

  J. S. Paulsen;H. Zhao;J. C. Stout;R. R. Brinkman

  259
  Citations

• Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease

  J. M. Wilson;A. I. Levey;A. Rajput;L. Ang

  251
  Citations

• [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease Implications for the symptomatic threshold

  M. Guttman;J. Burkholder;S. J. Kish;D. Hussey

  233
  Citations

• Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease

  Shannon A Johnson;Shannon A Johnson;Julie C Stout;Julie C Stout;Andrea C Solomon;Douglas R Langbehn

  232
  Citations

• Thalamic metabolism and symptom onset in preclinical Huntington's disease.

  A. Feigin;C. Tang;Y. Ma;P. Mattis

  223
  Citations

• Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease

  M. Guttman;I. Boileau;J. Warsh;J. A. Saint-Cyr

  220
  Citations

• Current concepts in the diagnosis and management of Parkinson's disease

  Mark Guttman;Stephen J. Kish;Yoshiaki Furukawa

  217
  Citations

• Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation

  Junchao Tong;Henry Wong;Mark Guttman;Lee C. Ang

  213
  Citations

• Dopa decarboxylase activity of the living human brain.

  Albert Gjedde;Jakob Reith;Suzan Dyve;Gabriel Leger

  207
  Citations

• Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C]DASB and structural brain imaging study

  Stephen J. Kish;Jason Lerch;Yoshiaki Furukawa;Junchao Tong

  201
  Citations

• Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD

  M. Guttman;D. Stewart;D. Hussey;A. Wilson

  199
  Citations

• Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.

  Junchao Tong;Gausiha Rathitharan;Jeffrey H Meyer;Yoshiaki Furukawa

  186
  Citations

• Burden of parkinsonism: a population-based study.

  Mark Guttman;Pamela M. Slaughter;Marc‐Erick Theriault;Donald P. DeBoer

  186
  Citations